TestGene has received Eurasian patent for the non-invasive prenatal testing of fetal RhD status using pregnant woman's blood.

NanoCenter subsidiary TestGene has received Eurasian patent for the non-invasive prenatal testing of fetal RhD status using pregnant woman's blood. The invention relates to medicine, molecular genetic testing DNA and can be used to determine fetal RhD status using blood of Rh-negative pregnant women. The intention of the proposed solution is to detect RhD gene of fetal DNA which are presented in human plasma in small amount. Diagnostic kit allows fetal Rhesus factor testing using maternal blood.

Eurasian patent system provides a uniform application procedure for physical and legal persons to protect their inventions on the basis of a single Eurasian patent valid in the territory of nine States party to the Eurasian Patent Convention (EAPC): Turkmenistan, Republic of Belarus, Republic of Tajikistan, Russian Federation, Republic of Kazakhstan, Republic of Azerbaijan, Kyrgyz Republic, Republic of Moldova, Republic of Armenia.

 Eurasian patents are granted for inventions created in all fields of science, technology and economy.

All the inventions are new, have achieved an inventive level and are industrially applicable.

The Eurasian Patent Convention entered into force on August 12, 1995

The main purpose of the EAPO is to create an interstate regional system of legal protection for inventions on the basis of a common Patent of Eurasia having legal effect on the territory of all the Contracting States of the Convention.